Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant PK in Hepatic Impairment
NCT06094725Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of relacorilant in Cushing's syndrome (3 arms), sponsored by Corcept Therapeutics. Primary endpoints: Maximum concentration of plasma relacorilant at Day 10 and Area under the concentration-time curve at Day 10. Started Jan 2020; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT06094725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094725.